Klin Farmakol Farm. 2010;24(3):121-123

Determination of imipenem plasmatic concentrations by high-performance liquid chromatography

Michal Šiller, Michal Lipš, Karel Urbánek
1 Ústav farmakologie LF UP a FN Olomouc
2 Klinika anesteziologie, resuscitace a intenzivní medicíny, Všeobecná fakultní nemocnice Praha

Imipenem is a high-effective broad-spectrum carbapenem antibiotic. The aim of our study was to introduce a reliable and simple

method for determination of imipenem plasma concentrations in our scientific laboratory. Plasma samples were stabilized by MOPS.

Elution was performed in gradient mode, mobile phase composed of potassium dihydrogenphosphate and methanol. Imipenem was

detected at 313 nm, no intereference of cilastatin or thienamycin was found. The basic validation parameters of method presented here

have been also determined.

Keywords: imipenem, high-performance liquid chromatography, pharmacokinetics, therapeutic monitoring

Published: October 15, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šiller M, Lipš M, Urbánek K. Determination of imipenem plasmatic concentrations by high-performance liquid chromatography. Klin Farmakol Farm. 2010;24(3):121-123.
Download citation

References

  1. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA. Comparative review of the carbapenems. Drugs. 2007; 67(7): 1027-1052. Go to original source... Go to PubMed...
  2. Moon YS, Chung KC, Gill MA. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Clin Infect Dis. 1997; 24(Suppl 2): S249-255. Go to original source... Go to PubMed...
  3. Jaruratanasirikul S, Sudsai T. Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion. J Antimicrob Chemother. 2009; 63(3): 560-563. Go to original source... Go to PubMed...
  4. Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, Sörgel F. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother. 2007; 51(9): 3304-3310. Go to original source... Go to PubMed...
  5. Fish DN, Teitelbaum I, Abraham E. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother. 2005; 49(6): 2421-2428. Go to original source... Go to PubMed...
  6. Garcia-Capdevila L, López-Calull C, Arroyo C, Moral MA, Mangues MA, Bonal J. Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patients. J Chromatogr B Biomed Sci Appl 1997; 692(1): 127-132. Go to original source... Go to PubMed...
  7. López KJ, Bertoluci DF, Vicente KM, Dell'Aquilla AM, Santos SR. Simultaneous determination of cefepime, vancomycin and imipenem in human plasma of burn patients by highperformance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 860(2): 241-245. Go to original source... Go to PubMed...
  8. Ratcliffe RW, Wildonger KJ, Di Michele L, Douglas AW, Hajdu R, Goegelman RT, Springer JP, Hirshfield J. Studies on the structures of imipenem, dehydropeptidase I-hydrolyzed imipenem, and related analogs. J. Organic Chemistry 1989; 54(3): 653-660. Go to original source...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.